Although we analyzed CDKN2A homozygous deletion using an NGS panel, it may be detected by a variety of methods, including fluorescence in situ hybridization (FISH), whole-exome sequencing, global DNA methylation profiling, and detecting potential loss of p16 immunoreactivity in tumor cell nuclei. The gene discussed is CDKN2A; the disease is neoplasm.